https://scholars.lib.ntu.edu.tw/handle/123456789/627205
Title: | Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial | Authors: | Verset, Gontran Borbath, Ivan Karwal, Mark Verslype, Chris Van Vlierberghe, Hans Kardosh, Adel Zagonel, Vittorina Stal, Per Sarker, Debashis Palmer, Daniel H Vogel, Arndt Edeline, Julien Cattan, Stephane Kudo, Masatoshi ANN-LII CHENG Ogasawara, Sadahisa Daniele, Bruno Chan, Stephen L Knox, Jennifer J Qin, Shukui Siegel, Abby B Chisamore, Michael Hatogai, Ken Wang, Anran Finn, Richard S Zhu, Andrew X |
Keywords: | SORAFENIB; BEVACIZUMAB; CRITERIA; PLUS | Issue Date: | 13-Jun-2022 | Publisher: | AMER ASSOC CANCER RESEARCH | Journal Volume: | 28 | Journal Issue: | 12 | Start page/Pages: | 2547 | Source: | Clinical cancer research : an official journal of the American Association for Cancer Research | Abstract: | KEYNOTE-224 cohort 1 demonstrated that pembrolizumab was efficacious and tolerable in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib. We report results from KEYNOTE-224 (NCT02702414) cohort 2, which enrolled patients with advanced HCC and no prior systemic therapy. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/627205 | ISSN: | 1078-0432 | DOI: | 10.1158/1078-0432.CCR-21-3807 |
Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.